Liquidia’s (LQDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $29.00 price objective on the stock.

Other analysts also recently issued reports about the company. Scotiabank assumed coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective for the company. Bank of America dropped their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Stock Performance

NASDAQ LQDA opened at $9.84 on Thursday. The business has a fifty day moving average price of $10.52 and a two-hundred day moving average price of $11.48. Liquidia has a fifty-two week low of $6.10 and a fifty-two week high of $16.99.

Insider Buying and Selling at Liquidia

In other Liquidia news, Director Caligan Partners Lp acquired 150,000 shares of Liquidia stock in a transaction that occurred on Friday, August 30th. The shares were bought at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. This trade represents a 2.19 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. California State Teachers Retirement System raised its holdings in Liquidia by 491.2% during the 1st quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock worth $681,000 after purchasing an additional 38,369 shares during the last quarter. Swiss National Bank bought a new position in Liquidia during the first quarter worth $1,325,000. Boston Partners bought a new position in Liquidia during the first quarter worth $762,000. Marshall Wace LLP acquired a new position in Liquidia in the second quarter valued at $545,000. Finally, Sapient Capital LLC bought a new stake in Liquidia during the third quarter valued at $1,336,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).